• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pre-exposure prophylaxis with 300 mg Evusheld elicits limited neutralizing activity against the Omicron variant.

作者信息

Benotmane Ilies, Velay Aurélie, Gautier-Vargas Gabriela, Olagne Jérôme, Thaunat Olivier, Fafi-Kremer Samira, Caillard Sophie

机构信息

Department of Nephrology and Transplantation, Strasbourg University Hospital, Strasbourg, France.

Department of Transplantation, Nephrology and Clinical Immunology, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.

出版信息

Kidney Int. 2022 Aug;102(2):442-444. doi: 10.1016/j.kint.2022.05.008. Epub 2022 May 24.

DOI:10.1016/j.kint.2022.05.008
PMID:35618094
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9126611/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d52f/9126611/7d7b860a1fb9/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d52f/9126611/f87e903d5b52/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d52f/9126611/7d7b860a1fb9/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d52f/9126611/f87e903d5b52/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d52f/9126611/7d7b860a1fb9/gr2_lrg.jpg

相似文献

1
Pre-exposure prophylaxis with 300 mg Evusheld elicits limited neutralizing activity against the Omicron variant.使用300毫克恩适得进行暴露前预防对奥密克戎变异株产生的中和活性有限。
Kidney Int. 2022 Aug;102(2):442-444. doi: 10.1016/j.kint.2022.05.008. Epub 2022 May 24.
2
Case report: Variant-specific pre-exposure prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responses.病例报告：缺乏疫苗应答的多发性硬化症患者中针对 SARS-CoV-2 感染的变异特异性预先暴露预防。
Front Immunol. 2022 Jul 25;13:897748. doi: 10.3389/fimmu.2022.897748. eCollection 2022.
3
mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant.mRNA 加强免疫可引发针对 SARS-CoV-2 奥密克戎变异株的强效中和血清活性。
Nat Med. 2022 Mar;28(3):477-480. doi: 10.1038/s41591-021-01676-0. Epub 2022 Jan 19.
4
Neutralizing antibody responses in vaccinated and unvaccinated individuals infected with Omicron BA.1 variant.感染奥密克戎BA.1变体的接种疫苗和未接种疫苗个体的中和抗体反应。
J Clin Virol. 2022 Oct;155:105253. doi: 10.1016/j.jcv.2022.105253. Epub 2022 Aug 3.
5
Omicron Variant Escapes Therapeutic Monoclonal Antibodies (mAbs) Including Recently Released Evusheld®, Contrary to 8 Prior Main Variant of Concern (VOC).与之前8种主要关注变异株（VOC）不同，奥密克戎变异株对治疗性单克隆抗体（mAbs）产生逃逸，包括最近获批的恩适得（Evusheld®）。
Clin Infect Dis. 2022 Aug 24;75(1):e534-e535. doi: 10.1093/cid/ciac143.
6
Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.感染或接种疫苗后针对 SARS-CoV-2 奥密克戎变异株的抗体亲合力和中和反应。
J Immunol Res. 2022 Aug 31;2022:4813199. doi: 10.1155/2022/4813199. eCollection 2022.
7
Glycosylation is required for the neutralizing activity of human IgG1 antibodies against human rabies induced by pre-exposure prophylaxis.糖基化对于人 IgG1 抗体针对人狂犬病的中和活性是必需的，这种中和活性是由暴露前预防诱导的。
Immunobiology. 2021 Mar;226(2):152058. doi: 10.1016/j.imbio.2021.152058. Epub 2021 Jan 23.
8
Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.评估 2 至 3 剂 BNT162b2 mRNA COVID-19 疫苗后针对 SARS-CoV-2 变异株的中和抗体反应。
JAMA Netw Open. 2022 May 2;5(5):e2210780. doi: 10.1001/jamanetworkopen.2022.10780.
9
[Not Available].[无可用内容]
MMW Fortschr Med. 2015 Jun;157 Suppl 2:8. doi: 10.1007/s15006-015-3159-2.
10
A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.一种糖基化 RBD 蛋白诱导针对奥密克戎和其他变体的增强型中和抗体，提高对 SARS-CoV-2 感染的保护作用。
J Virol. 2022 Sep 14;96(17):e0011822. doi: 10.1128/jvi.00118-22. Epub 2022 Aug 16.

引用本文的文献

1
A Microfluidic Strategy to Capture Antigen-Specific High-Affinity B Cells.一种捕获抗原特异性高亲和力B细胞的微流控策略。
Adv Nanobiomed Res. 2024 Jun;4(6):2300101. doi: 10.1002/anbr.202300101. Epub 2024 Apr 26.
2
Saliva Is a Sensitive and Accessible Sample Both for SARS-CoV-2 Detection and for the Evaluation of Treatment Effectiveness in Follow-Up Studies.唾液既是 SARS-CoV-2 检测的敏感且易于获取的样本，也可用于后续研究中评估治疗效果。
Viruses. 2024 Jun 27;16(7):1040. doi: 10.3390/v16071040.
3
Dietary Inulin to Improve SARS-CoV-2 Vaccine Response in Kidney Transplant Recipients: The RIVASTIM-Inulin Randomised Controlled Trial.
膳食菊粉改善肾移植受者对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗的反应：RIVASTIM-菊粉随机对照试验
Vaccines (Basel). 2024 Jun 3;12(6):608. doi: 10.3390/vaccines12060608.
4
Safety and efficacy of tixagevimab/cilgavimab for pre-exposure prophylaxis in kidney transplant recipients: a multicenter retrospective cohort study.替沙格韦单抗/西加韦单抗用于肾移植受者暴露前预防的安全性和有效性：一项多中心回顾性队列研究。
J Nephrol. 2024 Jul;37(6):1539-1550. doi: 10.1007/s40620-024-01889-9. Epub 2024 May 23.
5
Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No- or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy Better than Another?抗 SARS-CoV-2 单克隆抗体在无反应或弱反应疫苗接种的肾移植受者中的预先或暴露后应用：一种策略是否优于另一种？
Viruses. 2024 Feb 29;16(3):381. doi: 10.3390/v16030381.
6
Efficacy of Preexposure Prophylaxis with Monoclonal Antibody Tixagevimab-Cilgavimab against Emerging SARS-CoV-2 Resistant Variants in Patients with Chronic Lymphocytic Leukemia.替沙格韦单抗-西加韦单抗单克隆抗体预先暴露预防对慢性淋巴细胞白血病患者中出现的 SARS-CoV-2 耐药变异株的疗效。
Acta Haematol. 2024;147(6):634-645. doi: 10.1159/000537690. Epub 2024 Mar 12.
7
Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-CoV-2 in End-Stage Renal Disease Patients on Chronic Hemodialysis: A Single-Center Study.替沙格韦单抗和西加韦单抗（埃武利尤单抗）增强慢性血液透析终末期肾病患者对 SARS-CoV-2 的抗体水平：一项单中心研究。
Medicina (Kaunas). 2023 Dec 1;59(12):2109. doi: 10.3390/medicina59122109.
8
Adapting Neutralizing Antibodies to Viral Variants by Structure-Guided Affinity Maturation Using Phage Display Technology.利用噬菌体展示技术通过结构导向的亲和力成熟使中和抗体适应病毒变体
Glob Chall. 2023 Aug 21;7(10):2300088. doi: 10.1002/gch2.202300088. eCollection 2023 Oct.
9
Humoral vaccine response and breakthrough infections in kidney transplant recipients during the COVID-19 pandemic: a nationwide cohort study.新冠疫情期间肾移植受者的体液疫苗反应和突破性感染：一项全国性队列研究
EClinicalMedicine. 2023 Jun;60:102035. doi: 10.1016/j.eclinm.2023.102035. Epub 2023 Jun 6.
10
What has vaccination against COVID-19 in CKD patients taught us?接种 COVID-19 疫苗对慢性肾脏病患者有何启示？
J Nephrol. 2023 Jun;36(5):1257-1266. doi: 10.1007/s40620-023-01640-w. Epub 2023 May 4.